文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

联合抗生素治疗与单药治疗对ICU铜绿假单胞菌呼吸机相关性肺炎患者结局的关联:iDIAPASON试验的辅助研究

Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial.
PubMed 文献 · Crit Care · 2023-05-30
一句话结论在ICU铜绿假单胞菌呼吸机相关性肺炎患者中,联合抗生素治疗与单药治疗第90天死亡率相似(21.9%患者死亡,单药17例 vs 联合20例,P=0.180),但联合组机械通气时间更长(28±12天 vs 23±11天,P=0.0243)。

本研究为iDIAPASON试验的辅助研究,纳入169例接受适当抗生素治疗的铜绿假单胞菌呼吸机相关性肺炎患者,比较单药与联合抗生素治疗。主要终点第90天死亡率在两组间无显著差异:37例(21.9%)死亡患者中,单药组17例,联合组20例(P=0.180)。两组在VAP复发率、肺外感染数量及ICU期间多重耐药菌获得方面相似。联合治疗组机械通气时间显著长于单药组(28±12天 vs 23±11天,P=0.0243)。作者认为,除抗生素治疗和机械通气时间更长外,联合治疗组结局与单药组相似。

要点

  • 第90天死亡率:37例(21.9%)死亡,其中单药组17例、联合组20例(P=0.180),两组无显著差异。
  • 联合治疗组机械通气时间28±12天,显著长于单药组的23±11天(P=0.0243)。
  • 两组VAP复发率、肺外感染数量及ICU期间多重耐药菌获得相似。
  • 适当抗生素治疗的中位持续时间为14天。
  • 校正iDIAPASON试验随机分组和ICU入院时SOFA评分后,结果仍相似。

适用人群与场景

  • 纳入iDIAPASON试验(比较多粘菌素8天 vs 15天疗程)的铜绿假单胞菌呼吸机相关性肺炎患者,且接受适当抗生素治疗者;共169例纳入本分析。

研究设计与关键结果

  • 研究类型:iDIAPASON多中心随机对照试验的辅助研究;样本量169例;人群为铜绿假单胞菌呼吸机相关性肺炎且接受适当抗生素治疗的ICU患者;比较单药 vs 联合抗生素治疗。
  • 主要终点第90天死亡率:37例(21.9%)死亡,其中单药组17例、联合组20例(P=0.180)。
  • 适当抗生素治疗的中位持续时间为14天。
  • 联合治疗组机械通气时间28±12天,单药组23±11天(P=0.0243)。
  • 两组VAP复发率、肺外感染数量及ICU期间多重耐药菌获得相似。
  • 校正iDIAPASON试验随机分组和ICU入院时SOFA评分后,结果仍相似。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验的辅助研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,除抗生素治疗和机械通气时间更长(可能与临床治愈难度增加有关)外,联合治疗组结局与单药组相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal treatment duration and the nature of regimen of antibiotics (monotherapy or combination therapy) for Pseudomonas aeruginosa ventilator‑associated pneumonia (PA-VAP) remain debated. The aim of this study was to evaluate whether a combination antibiotic therapy is superior to a monotherapy in patients with PA-VAP in terms of reduction in recurrence and death, based on the 186 patients included in the iDIAPASON trial, a multicenter, randomized controlled trial comparing 8 versus 15 days of antibiotic therapy for PA-VAP.

METHODS: Patients with PA-VAP randomized in the iDIAPASON trial (short-duration-8 days vs. long-duration-15 days) and who received appropriate antibiotic therapy were eligible in the present study. The main objective is to compare mortality at day 90 according to the antibiotic therapy received by the patient: monotherapy versus combination therapy. The primary outcome was the mortality rate at day 90. The primary outcome was compared between groups using a Chi-square test. Time from appropriate antibiotic therapy to death in ICU or to censure at day 90 was represented using Kaplan-Meier survival curves and compared between groups using a Log-rank test.

RESULTS: A total of 169 patients were included in the analysis. The median duration of appropriate antibiotic therapy was 14 days. At day 90, among 37 patients (21.9%) who died, 17 received monotherapy and 20 received a combination therapy (P = 0.180). Monotherapy and combination antibiotic therapy were similar for the recurrence rate of VAP, the number of extra pulmonary infections, or the acquisition of multidrug-resistant (MDR) bacteria during the ICU stay. Patients in combination therapy were exposed to mechanical ventilation for 28 ± 12 days, as compared with 23 ± 11 days for those receiving monotherapy (P = 0.0243). Results remain similar after adjustment for randomization arm of iDIAPASON trial and SOFA score at ICU admission.

CONCLUSIONS: Except longer durations of antibiotic therapy and mechanical ventilation, potentially related to increased difficulty in achieving clinical cure, the patients in the combination therapy group had similar outcomes to those in the monotherapy group.

TRIAL REGISTRATION: NCT02634411 , Registered 15 December 2015.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Foucrier A, Dessalle T, Tuffet S, et al. Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Crit Care. 2023. PMID: 37254209. doi:10.1186/s13054-023-04457-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。